Jan-Henrik Mikesch
Geboren:
1976
Hat mitgewirkt an:
-
The Burden of Survivorship on Hematological Patients—Long-Term Analysis of Toxicities after Total Body Irradiation and Allogeneic Stem Cell Transplantation
-
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
-
A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
-
Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report